Description
Pantoprazole is the third proton pump inhibitor marketed globally. Compared with omeprazole, it has higher selectivity and bioavailability. Pantoprazole is more stable than omeprazole and lansola under weak acid conditions. The product of Pantoprazole, developed by Byk Gulden of Germany, can treat duodenal ulcer; gastric ulcer; moderate and severe reflux esophagitis. It was approved for listing in China in 1999. By the end of 2020, there are several manufacturers in the Chinese Pantoprazole market.
According to CRI’s market research, the sales value of pantoprazole in the Chinese market has declined continuously from 2016 to 2020, and its sales value reached CNY 1.162 billion in 2020. The sales value of pantoprazole in the Chinese market has shown an overall upward trend from 2016 to 2020, with a CAGR of 3.06% from 2016 to 2020.
CRI expects that with the effective alleviation of the COVID-19 epidemic, the sales of pantoprazole will have a restorative growth from 2016 to 2020. Pantoprazole has the advantages of stable curative effect, good acid suppression effect, and small short-term side effects. Therefore, the sales of pantoprazole in China will maintain a growth trend in the future.
Topics Covered:
-The impact of COVID-19 on China’s Pantoprazole market
– Sales value of China’s Pantoprazole 2016-2020
– Competitive landscape of China’s Pantoprazole market
– Prices of Pantoprazole in China
– Prices of Pantoprazole in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Pantoprazole market
– Prospect of China’s Pantoprazole market from 2021 to 2025
